Pitavastatin
- Generic Name
- Pitavastatin
- Brand Names
- Livalo, Zypitamag
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24FNO4
- CAS Number
- 147511-69-1
- Unique Ingredient Identifier
- M5681Q5F9P
- Background
Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competiti...
- Indication
用于治疗高胆固醇症(高脂血症)、家族性高胆固醇症。
- Associated Conditions
- Apolipoprotein B increased, Elevation of serum triglyceride levels, Increases in serum total low-density lipoprotein (LDL), Increases in total cholesterol
- Associated Therapies
- -
Effect of Pitavastatin on Bone
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06359353
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- C.Dirven
- Target Recruit Count
- 12
- Registration Number
- NCT05977738
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial
- Conditions
- Interventions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 250
- Registration Number
- NCT05705804
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-02-26
- Target Recruit Count
- 80
- Registration Number
- NCT05537948
- Locations
- 🇷🇺
National Medical Research Centre for Therapy and Preventive Medicine of the Ministry of Health of Russia, Moscow, Russian Federation
Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in AMI Patients With Abnormal Glucose Metabolism
- Conditions
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2022-05-12
- Target Recruit Count
- 900
- Registration Number
- NCT04945122
- Locations
- 🇨🇳
Fuwai Hospital, Beijing, Beijing, China
Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 60
- Registration Number
- NCT04705909
- Locations
- 🇪🇬
Faculty of pharmacy, Mansoura university, Mansoura, Egypt
Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Orient Pharma Co., Ltd.
- Target Recruit Count
- 390
- Registration Number
- NCT04643093
- Locations
- 🇨🇳
E-Da Hospital, Kaohsiung, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Tri-Service General Hospital, Taipei, Taiwan
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 6
- Registration Number
- NCT04512105
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
Efficacy and Safety of Pitavastatin in a Real-world Setting
- Conditions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 28343
- Registration Number
- NCT04402112
A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT03717064
- Locations
- 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.